Serum Urate Testing Following Urate-Lowering Therapy
Identifying Attributes
Care Settings
Country
Publishing Organisation
Type of Quality Indicator
IOM Quality Dimension
Domain
Defining Attributes
Definition
Serum urate testing in the six months following urate-lowering therapy dispensing, by DHB (percent)
Numerator
Number of people with identified gout aged 20 years and over who had a recorded serum urate laboratory test in the six months following gout specific urate-lowering therapy (allopurinol, febuxostat, benzbromarone) dispensing.
Denominator
Those aged 20 years and over with identified gout using the HealthTracker method who were dispensed urate-lowering therapy in a year.
Exclusions
People not enrolled with a PHO in each year.
Use of Risk Adjustment
Risk Adjustments
Stratifications
By year (2012-2019), age group (20-44, 45-64, 65+) and ethnicity (Māori, Pacific peoples, non-Māori, non-Pacific).
Collection and Reporting Attributes
Type of Data Collection
Data Collection Methods
Ministry of Health: National Minimum Dataset, Pharmaceutical Collection, PHO enrolments, Mortality Collection, New Zealand Cancer Registry.
Frequency of Data Collection
Frequency of Data Collection in Days
Reporting Methods
Atlas of Healthcare Variation website